Free tool
Oncology stocks
We cover 31 companies grouped under the Oncology theme. The median market value in the group is $6.39B. Across the group, the median move over the past trading day is +1.97%. 87% of the 31 with a 200-day average trade above it. Price change over the past year runs from −14.4% to +486.0% across the middle 80 percent of the group, with a median of +79.6%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
31 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | $67.92 | +8.57% | +28.36% | +49.31% | Oct 29, 2026 |
| 4519.T | Chugai Pharmaceutical Co., Ltd. | 7,050.00 JPY | +0.73% | −17.21% | +12.47% | Oct 27, 2026 |
| RVMD | Revolution Medicines, Inc. | $211.38 | +12.39% | +167.50% | +492.60% | Nov 4, 2026 |
| ONC | BeOne Medicines AG | $376.37 | +15.49% | +21.01% | +21.95% | Nov 5, 2026 |
| 4568.T | Daiichi Sankyo Company, Limited | 2,923.00 JPY | +1.16% | −16.08% | −15.95% | Oct 30, 2026 |
| BNTX | BioNTech SE | $114.05 | +25.21% | +17.95% | +8.55% | Nov 3, 2026 |
| INCY | Incyte Corporation | $129.72 | +9.13% | +27.90% | +53.04% | Oct 27, 2026 |
| GMAB | Genmab A/S | $34.36 | +19.31% | +7.98% | +41.34% | Nov 5, 2026 |
| GE9.DE | GENMAB AS N | 283.30 EUR | +10.97% | +5.71% | −14.41% | Nov 5, 2026 |
| 0J9P.L | Incyte Corporation | $130.13 | +1.97% | +30.41% | +53.55% | Oct 27, 2026 |
| EXEL | Exelixis, Inc. | $56.72 | +1.63% | +30.15% | +49.66% | Oct 27, 2026 |
| 0IJO.L | Exelixis, Inc. | $56.16 | +3.33% | +30.00% | +44.33% | Oct 27, 2026 |
| SMMT | Summit Therapeutics Inc. | $13.36 | +1.95% | −23.74% | −49.14% | Oct 19, 2026 |
| 4528.T | Ono Pharmaceutical Co., Ltd. | 2,511.00 JPY | +3.89% | +16.57% | +62.22% | Oct 29, 2026 |
| LNTH | Lantheus Holdings, Inc. | $100.87 | −6.63% | +49.95% | +79.61% | Nov 5, 2026 |
| COGT | Cogent Biosciences, Inc. | $36.80 | −9.00% | +5.93% | +212.13% | Nov 3, 2026 |
| ERAS | Erasca, Inc. | $17.76 | −5.88% | +394.71% | +1016.98% | Nov 11, 2026 |
| RLAY | Relay Therapeutics, Inc. | $20.57 | +10.35% | +151.47% | +486.04% | Nov 5, 2026 |
| CELC | Celcuity Inc. | $92.27 | +12.16% | −8.23% | +87.35% | Nov 11, 2026 |
| TNGX | Tango Therapeutics, Inc. | $24.51 | −8.27% | +174.47% | +264.73% | Nov 4, 2026 |
| RCUS | Arcus Biosciences, Inc. | $31.57 | +13.40% | +35.55% | +211.03% | Oct 27, 2026 |
| IMNM | Immunome, Inc. | $29.39 | +30.14% | +41.14% | +196.22% | Nov 5, 2026 |
| ZLAB | Zai Lab Limited | $26.17 | +40.40% | +51.01% | −23.10% | Nov 5, 2026 |
| SLS | SELLAS Life Sciences Group, Inc. | $14.09 | +29.98% | +223.91% | +637.70% | Nov 11, 2026 |
| NRIX | Nurix Therapeutics, Inc. | $26.95 | +15.02% | +49.22% | +178.70% | Oct 8, 2026 |
| NUVB | Nuvation Bio Inc. | $7.10 | +6.61% | −17.25% | +146.53% | Nov 2, 2026 |
| URGN | UroGen Pharma Ltd. | $46.36 | +11.82% | +104.14% | +150.59% | Nov 5, 2026 |
| XNCR | Xencor, Inc. Common Stock | $29.30 | +47.53% | +96.38% | +265.79% | Nov 4, 2026 |
| NANO.PA | Nanobiotix S.A. | 34.14 EUR | +3.96% | +79.68% | +341.09% | Sep 29, 2026 |
| NBTX | Nanobiotix S.A. | $41.51 | +3.31% | +87.57% | +321.42% | Sep 29, 2026 |
| NVCR | NovoCure Limited | $17.62 | +3.46% | +34.30% | +50.60% | Oct 29, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.